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Abstract
It has been estimated by the World Health Organization (WHO) that over 71 million people were infected with the hepatitis C 
virus (HCV) in 2015. Since then, a number of highly effective direct-acting antiviral (DAA) regimens have been licensed 
for the treatment of chronic HCV infection: sofosbuvir/daclatasvir, sofosbuvir/ledipasvir, elbasvir/grazoprevir, sofosbuvir/
velpatasvir, glecaprevir/pibrentasvir, and sofosbuvir/velpatasvir/voxilaprevir. With these treatment regimens, almost all 
chronic HCV-infected patients, even including prior DAA failures, can be treated effectively and safely. It is therefore 
likely that further development of DAAs will be limited. In this descriptive review we provide an overview of the clinical 
pharmacokinetic characteristics of currently available DAAs by describing their absorption, distribution, metabolism, and 
excretion. Potential drug–drug interactions with the DAAs are briefly discussed. Furthermore, we summarize what is known 
about the pharmacodynamics of the DAAs in terms of efficacy and safety. We briefly discuss the relationship between the 
pharmacokinetics of the DAAs and efficacy or toxicity in special populations, such as hard to cure patients and patients with 
liver cirrhosis, liver transplantation, renal impairment, hepatitis B virus or HIV co-infection, bleeding disorders, and children. 
The aim of this overview is to educate/update prescribers and pharmacists so that they are able to safely and effectively treat 
HCV-infected patients even in the presence of underlying co-infections or co-morbidities.
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Key Points 
The currently approved direct-acting antivirals 
(DAAs) can be used to treat a great majority of hepati-
tis C-infected patients.
Some of the last remaining issues regarding DAA 
therapy are how to treat patients who have not responded 
to DAA therapy who have severe resistance associated-
substitution, how to manage drug interactions with 
strong enzyme inducers, and how to treat patients with 
both decompensated cirrhosis and renal impairment.
1 Introduction
Hepatitis C virus (HCV) infection is caused by a virus that 
replicates in the liver; this leads to scarring of the liver 
which can result in liver diseases such as cirrhosis and hepa-
tocellular carcinoma. In 2015, it was estimated by the World 
Health Organization (WHO) that over 71 million people 
were infected with HCV (HCV-RNA positive) [1]. In addi-
tion, from 1988 to 2009, 59% of liver transplantations were 
caused by cirrhosis, of which 40% were virus related [2].
HCV is an RNA virus that can be divided in six geno-
types with several subtypes. Recently, a case report of a 
seventh HCV genotype has been described [3]. Treatment 
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success and development of liver disease differs per geno-
type. Another important aspect is the high replication rate 
and the error-prone nature of the HCV viral replication 
cycles. This results in a high prevalence of resistance-associ-
ated substitutions (RASs), which can occur with and without 
drug pressure [4].
The landscape of HCV therapy dramatically changed 
from 2015 onwards. Before 2015, the treatment of HCV 
was mainly with peg-interferon (peg-IFN) plus ribavirin 
(RBV) therapy, which was associated with suboptimal 
response rates and considerable short- and long-term toxic-
ity. HCV cure rates markedly improved with the approval 
of boceprevir and telaprevir, the first direct-acting antivirals 
(DAAs), but toxicity was still high [5]. Since the approval 
of these drugs, several other DAAs have been licensed, with 
a further increase in response rates for the different HCV 
genotypes and special patient populations. The timeline of 
DAA development is presented in Fig. 1.
With the recent approval of the highly effective regimens 
of glecaprevir (GLE)/pibrentasvir (PIB) [6] and sofosbuvir 
(SOF)/velpatasvir (VEL) [7] with or without voxilaprevir 
(VOX) [8], more than 95% of chronic HCV-infected patients 
can be treated successfully and safely. A remaining challenge 
is drug pricing, which is still limiting HCV treatment access 
globally. Clinical challenges in HCV treatment only remain 
in a few special patient groups such as patients with decom-
pensated cirrhosis, renal impairment, and drug–drug interac-
tions (DDIs). Nevertheless, further DAA drug development 
has seemingly ended, with few DAAs left in the development 
pipelines of the major drug companies. The drugs licensed 
today are the regimens that we will use to reach the WHO 
goals to eliminate and eradicate HCV [1]. To accomplish this, 
the biggest challenge in resource-rich countries is to identify 
all patients who are HCV infected and lost from care or those 
who were never diagnosed. For the low-income countries, the 
availability of these drugs is often a major issue because of 
high pricing.
The aim of this descriptive review is to give an overview 
of the pharmacokinetics and pharmacodynamics (safety 
and efficacy) of the DAAs currently used for chronic HCV 
treatment. In addition, special populations are identified and 
separately discussed.
2  Methods
All phase II and III studies describing efficacy and/or safety 
of the following DAA combinations were selected for this 
review: SOF/daclatasvir (DCV); SOF/ledipasvir (LDV); 
elbasvir (EBR)/grazoprevir (GZR); SOF/VEL; GLE/PIB; 
and SOF/VEL/VOX. Boceprevir, telaprevir, simeprevir, 
and paritaprevir/ritonavir, ombitasvir, dasabuvir are not dis-
cussed as they have been withdrawn (licensed not extended) 
from the market and no generic versions of these DAAs will 
be produced. Retrospective studies and case reports/series 
were excluded. In addition, the Summaries of Product Char-
acteristics (SmPCs) published by the European Medicines 
Agency (EMA), the prescribing information published by 
the US Food and Drug Administration (FDA), and poster 
presentations available online were used.
The overview of the search terms and results can be found 
in the Electronic Supplementary Material (ESM) (Table S1), 
as well as the summary of the efficacy and safety data found 
in the studies (ESM Table S3–S8).
3  Pharmacokinetics
Table 1 presents a summary of the product and dosing 
information of the DAAs approved by the FDA and EMA. 
Table 2 provides an overview of the pharmacokinetic param-
eters of the DAAs. 
3.1  Daclatasvir (DCV)
3.1.1  Absorption
DCV is readily absorbed as the time to maximal plasma 
concentration (tmax) is 1–2 h. The maximal plasma con-
centration (Cmax), area under the concentration–time curve 
(AUC), and minimal plasma concentration (Cmin) increase 
in a dose-proportional matter. Exposure was comparable in 
HCV-infected patients and healthy volunteers after a dosage 
of 60 mg [9, 10]. A high-fat meal (950 kcal; 492 kcal fat, 
312 kcal carbohydrates, 144 kcal protein) decreases absorp-
tion as both the Cmax and AUC decreased (28% and 23%, 
Fig. 1  Timeline of approval of direct-acting antivirals for both the US 
Food and Drug Administration (FDA) and the European Medicines 
Agency (EMA). 1Drugs are withdrawn or were not re-approved for 
the EMA and/or FDA markets
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respectively). No effect on absorption of a low-fat meal was 
observed (277 kcal; 42 kcal fat, 190 kcal carbohydrates, and 
44 kcal proteins). In vitro data have shown that DCV is a 
substrate of the transporter P-glycoprotein (P-gp) (Caco-2 
cells) and the absolute bioavailability is 67% [10].
DCV is combined with SOF  (Sovaldi®). SOF is quickly 
absorbed and the median Cmax was found after ~ 0.5–2 h. 
Table 1  Summary of product and dosing information for the direct-acting antivirals approved by the US Food and Drug Administration and 
European Medicines Agency
qd once daily
Drug Brand name Pharmaceutical 
form
Dose Genotypes Remarks References
Daclatasvir Daklinza® Film-coated tablet 60 mg qd 1a, 1b, 2, 3, 4 Available in tablets 
of 30, 60, and 
90 mg
[9, 10]
Sofosbuvir/ledi-
pasvir
Harvoni® Film-coated tablet 400 mg/90 mg qd 1a, 1b, 4, 5, 6 [15, 16]
Elbasvir/grazo-
previr
Zepatier® Film-coated tablet 50 mg/100 mg qd 1a, 1b, 4 [17, 18]
Sofosbuvir/vel-
patasvir
Epclusa® Film-coated tablet 400 mg/100 mg 1a, 1b, 2, 3, 4, 5, 6 [7, 19]
Glecaprevir/pibren-
tasvir
Maviret®/Mavyret® Film-coated tablet 100 mg/40 mg qd 1a, 1b, 2, 3, 4, 5, 6 [6, 20]
Sofosbuvir/vel-
patasvir/voxil-
aprevir
Vosevi® Film-coated tablet 400 mg/100 mg/100 mg 1a, 1b, 2, 3, 4, 5, 6 [8, 21]
Table 2  Summary of pharmacokinetic parameters for the direct-acting antivirals approved by the US Food and Drug Administration and Euro-
pean Medicines Agency
Primary data were used from the SmPC and FDA prescribing information concerning HCV-infected patients without cirrhosis
AUC area under the concentration–time curve, Cmax maximal plasma concentration, Cmin minimal plasma concentration, FDA US Food and 
Drug Administration, NR data were not reported and/or available in the SmPC and FDA prescribing information, SmPC Summary of Product 
Characteristics, t½ elimination half-life, tmax time to maximal plasma concentration, Vd/F volume of distribution
Drug tmax (h) Cmax (ng/mL) Cmin (ng/mL) AUC (ng∙h/mL) Vd/F t½ (h) Protein binding (%) References
Protease inhibitors
 Glecaprevir 5.0 597 NR 4800 NR 6–9 97 [6, 20]
 Grazoprevir 2 165 18.0 1420 1250 24 > 98.8 [17, 18]
 Voxilaprevir 4 192 47 2577 NR 33 > 99 [8, 21]
NS5A inhibitors
 Daclatasvir 1–2 1534 232 14,122 47 12–15 ± 99 [9, 10]
 Elbasvir 3 121 48.4 1920 680 31 > 99.9 [17, 18]
 Ledipasvir 4.0 323 NR 7290 47 > 99.8 [15, 16]
 Pibrentasvir 5.0 110 NR 1430 NR 23–29 > 99.9 [6, 20]
 Velpatasvir  (Epclusa®) 3 259 51 2970 NR 15 > 99.5 [7, 19]
 Velpatasvir  (Vosevi®) 4 311 NR 4041 NR 17 > 99 [8, 21]
NS5B inhibitors
 Sofosbuvir/GS-331007  (Sovaldi®) 0.5–2/2 NR NR 1010/7200 NR 0.4/27 61–65/minimal [11, 12]
 Sofosbuvir/GS-331007  (Harvoni®) ~ 1/4 618/707 NR 1320/12,000 NR 0.5/27 61–65/minimal [15, 16]
 Sofosbuvir/GS-331007  (Epclusa®) 0.5–1/3 566/868 NR 1260/13,970 NR 0.5/25 61–65/minimal [7, 19]
 Sofosbuvir/GS-331007  (Vosevi®) 2/4 678/744 NR 1665/12,834 NR 0.5/29 61–65/minimal [8, 21]
GS-331007 is the main circulating metabolite of SOF and 
frequently used to describe the pharmacokinetics of SOF. 
The Cmax of GS-331007 was found 2–4 h after administra-
tion. The exposure of SOF and GS-331007 were 57% higher 
and 39% lower when HCV-infected subjects were compared 
with healthy volunteers. Food increased SOF absorption by 
a factor of 1.8; however, there were no clinically relevant 
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alterations in Cmax. GS-331007 was not affected by food. The 
AUC of SOF and GS-331007 show a near dose-proportional 
increase in the range of 200–1200 mg. SOF is a substrate 
of the transporters P-gp and breast cancer resistance protein 
(BCRP). This is not the case for GS-331007 [11, 12].
3.1.2  Distribution
DCV is highly bound to plasma proteins (~ 99%) and the 
apparent volume of distribution (Vd/L) is 47.1 L. DCV is 
passively and actively transported into hepatocytes. In vitro 
data have shown that DCV is actively transported by organic 
cation transporter (OCT) 1 and inhibits P-gp, organic anion 
transporting protein (OATP) 1B1, and BCRP. DCV also 
in vitro inhibits the renal transporters organic anion trans-
porter (OAT) 1, OAT3, and OCT2 [9, 10]. OCT2 inhibition 
by DCV is not clinically relevant, as shown in a drug interac-
tion study with metformin (an OCT1 and OCT2 substrate) 
[13].
SOF is 61–65% bound to plasma proteins and the binding 
of SOF is independent of drug concentrations (1–20 µg/mL). 
GS-331007 is minimally bound to plasma proteins [11, 12] .
3.1.3  Metabolism
DCV is a substrate of cytochrome P450 (CYP) 3A4; how-
ever, 97% of the circulating drug is the parent drug and < 5% 
of metabolites are found in plasma [9, 10].
SOF has a more complex metabolism (see Fig. 2) [14]. 
SOF is initially metabolized in the liver into the pharmaco-
logically active nucleoside analog triphosphate GS-461203. 
This is followed by dephosphorylation to the main inactive 
metabolite GS-331007. GS-331007 accounts for over 90% 
of the systemic exposure. SOF only accounts for 4% of the 
systemic exposure [11, 12].
3.1.4  Excretion
DCV is primarily hepatically cleared, as 88% of a radioac-
tive test dose was retrieved in the feces, of which 53% was 
the parent drug. Only 6.6% of the parent drug was excreted 
in the urine. The elimination half-life (t½) is 12–15 h and the 
clearance is 4.24 L/h [9, 10].
For SOF, the main route of excretion is via urine (80%); 
only 14% of a radioactive dose was recovered in feces. The 
majority was retrieved as GS-331007 (78%) and only 3.5% 
2013 
2014 
2015 2017 
2018 2016 
Boceprevir1 
FDA May 
EMA August 
Telaprevir1 
FDA May 
EMA October 
Paritaprevir/ritonavir, 
ombitasvir 
FDA July 
EMA March1 
Dasabuvir 
EMA February1 
Glecaprevir, 
pibrentasvir 
FDA August 
EMA August 
Sofosbuvir, velpatasvir, 
voxilaprevir 
EMA September 
Simeprevir1 
FDA November 
EMA June 
Daclatasvir 
EMA September 
Ledipasvir, sofosbuvir 
FDA October 
EMA December 
Sofosbuvir 
EMA September 
2011 
Sofosbuvir 
FDA December 
Sofosbuvir, velpatasvir 
FDA June 
EMA July 
Daclatasvir 
FDA July 
Elbasvir, grazoprevir 
FDA January 
EMA July 
Sofosbuvir, velpatasvir, 
voxilaprevir 
FDA July 
Paritaprevir/ritonavir, 
ombitasvir, dasabuvir 
FDA December 
Fig. 2  Metabolism of sofosbuvir (derived from Kirby et al. [14])
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was recovered as the parent drug. The median t½ was 0.4 h 
for SOF and 27 h for GS-331007 [11, 12].
3.2  Sofosbuvir (SOF)/Ledipasvir (LDV)
When interpreting the SOF pharmacokinetic data it is 
important to recognize that the different formulations (e.g., 
 Sovaldi®,  Harvoni®,  Epclusa®,  Vosevi®) all have their own 
pharmacokinetic profiles and therefore there are slight dif-
ferences in the described parameters within this review. See 
also Table 2 for a complete overview.
3.2.1  Absorption
The pharmacokinetics of the fixed-dose tablet SOF/LDV 
 (Harvoni®) are described in this section. The LDV Cmax was 
reached after 4–4.5 h. The tmax of SOF was ~ 1 h after drug 
intake. The main inactive metabolite of SOF, GS-331007 
(see Sect. 3.2.3) had a tmax of 4 h. The exposure of both 
GS-331007 and LDV were comparable between healthy vol-
unteers and HCV-infected patients. The exposure of LDV 
and GS-331007 are not affected by moderate- (600 kcal; 
30% fat) and high- (1000 kcal; 50% fat) fat meals. However, 
the AUC from time zero to infinity (AUC ∞) of SOF when 
taken with food was increased ~ 2-fold but the Cmax of SOF 
was not affected [15, 16]. Despite these differences, response 
rates with and without food are comparable so SOF/LDV 
can be administered with or without food [16]. In addition, 
the solubility of LDV decreases with an increase of pH. 
Lastly, both SOF and LDV are substrates of the drug trans-
porters P-gp and BCRP [15, 16].
3.2.2  Distribution
LDV and SOF are both bound to plasma proteins: > 99.8% 
and 61–65%, respectively. GS-331007 is not bound to 
plasma proteins. LDV is an inhibitor of the intestinal trans-
porters P-gp and BCRP. In addition, OATP1B1/2 and bile 
salt export pump are inhibited [15, 16].
3.2.3  Metabolism
The metabolism of LDV is unknown, but is expected to be 
minimal as > 98% of the parent drug is responsible for sys-
temic exposure [15, 16].
SOF has a more complex metabolism (see Fig. 2 and 
Sect. 3.1.3) [14]. SOF is metabolized in the liver into the 
pharmacologically active nucleoside analog triphosphate 
GS-461203. Dephosphorylation results in the main inactive 
metabolite, GS-331007. GS-331007 accounts for over 90% 
of the systemic exposure [15, 16].
3.2.4  Excretion
After a radioactive dose of LDV, 87% of the parent drug was 
retrieved in urine and feces, of which 86% was in feces. The 
median t½ was 47 h [15, 16].
For SOF the main route of excretion is via urine (80%); 
only 14% of a radioactive dose was recovered in feces. The 
majority was retrieved as GS-331007 (78%) and only 3.5% 
was found as the parent drug. The median t½ was 0.5 h for 
SOF and 27 h for GS-331007 [15, 16].
3.3  Elbasvir (EBR)/Grazoprevir (GZR)
3.3.1  Absorption
The median tmax of EBR is 3 h (range 3–6 h) and the esti-
mated bioavailability is ~ 32%. A high-fat meal (900 kcal; 
500 kcal fat) decreased absorption (AUC 11% and Cmax 
15%). EBR is a substrate of P-gp.
The median tmax for GZR is 2 h (range 0.5–3 h) and the 
absolute bioavailability after a single dose varied from 15 
to 27% and after multiple doses from 20 to 40%. A high-fat 
meal (900 kcal; 500 kcal fat) increased absorption (AUC 
50% and Cmax 108%). When compared with healthy indi-
viduals, HCV-infected patients had increased exposure 
(~ 2-fold). GZR is a substrate of P-gp. Steady state is reached 
around the sixth day of administration [17, 18].
3.3.2  Distribution
EBR and GZR are highly bound to both albumin and α1-
acid glycoprotein (> 99.9% and > 98.8%, respectively) [17, 
18]. The estimated Vd/L values for EBR and GZR are 680 
and 1250 L, respectively. GZR is actively transported by the 
hepatic transporter OATP1B1/3 [18]. Although EBR inhibits 
P-gp, it is not clinically relevant as shown in a drug inter-
action study with digoxin (11% increase of digoxin). Both 
drugs inhibit BCRP [17, 18].
3.3.3  Metabolism
Both EBR and GZR are substrates of CYP3A4; however, no 
circulating metabolites were detected in plasma. GZR is a 
weak inhibitor of CYP3A4 [17, 18].
3.3.4  Excretion
Both EBR and GZR are primary hepatically cleared as > 99% 
of a radioactive dose was retrieved in feces. The apparent t½ 
is 24 and 31 h for EBR and GZR, respectively [17, 18].
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3.4  SOF/Velpatasvir (VEL)
3.4.1  Absorption
The pharmacokinetics of the fixed-dose tablet SOF/VEL 
 (Epclusa®) is described in this section.
The SOF Cmax was found 0.5–1 h after administration 
and the GS-331007 Cmax was found 3 h after administration. 
The exposures of SOF and GS-331007 were comparable in 
healthy volunteers and HCV-infected patients. A moderate- 
and high-fat meal increased the AUC ∞ of SOF by 60% and 
78%, respectively. However, the SOF Cmax was not affected 
by food and the GS-331007 AUC ∞ was decreased by 25% 
and 37%, respectively [7, 19].
The median tmax of VEL is 3 h and the AUC and Cmax 
values were 41% and 37% lower in healthy volunteers than 
in HCV-infected patients. The VEL AUC was increased 
34% and 21% after intake of moderate- (600 kcal; 30% fat) 
and high-fat (800 kcal; 50% fat) meals; the Cmax was only 
increased by 34% and 5%, respectively. In addition, VEL has 
pH-dependent solubility and the solubility (and thus absorp-
tion) decreases with increasing pH [7, 19].
3.4.2  Distribution
VEL is highly protein bound (> 99.5%), which is independ-
ent of the concentration range of 0.09–1.8 µg/mL. SOF is 
a substrate of P-gp and BCRP and VEL is a substrate of 
P-gp, OATP1B, and BCRP [7, 19]. SOF is bound 61–65% 
to plasma proteins, which is dose independent (1–20 µg/mL) 
[7, 19].
3.4.3  Metabolism
VEL is metabolized by CYP2B6, CYP2C8, and CYP3A4. 
However, after a single dose > 98% of the parent drug was 
found in the blood. VEL is an inhibitor of P-gp, BCRP, and 
OATP1B1/3 [7, 19].
SOF metabolism is discussed in Sect. 3.1.3.
3.4.4  Excretion
As > 94% of VEL was retrieved in feces and 0.4% in urine, 
clearance of VEL is mainly hepatic. 77% of VEL was recov-
ered in feces as the parent drug. The t½ of VEL is around 
15 h [7, 19]. SOF is mainly renally excreted (80%) and the 
majority of the dose found was GS-331007 (78%); only 
3.5% was found as SOF. The t½ of SOF was 0.5 h and for 
GS-331007 was 25 h [7, 19].
3.5  Glecaprevir (GLE)/Pibrentasvir (PIB)
3.5.1  Absorption
The tmax of GLE/PIB is approximately 5 h and food increases 
absorption (both moderate- and high-fat meals). GLE expo-
sure was increased 83–163% and PIB 40–53% when taken 
with a meal. Both drugs are P-gp substrates [6, 20].
3.5.2  Distribution
GLE and PIB are highly bound to plasma proteins 
(GLE 97.5%; PIB > 99.9%) and actively transported by 
BCRP. GLE is also a substrate for the hepatic transporter 
OATP1B1/3 [6, 20].
3.5.3  Metabolism
GLE is metabolized by CYP3A4 and PIB is not subject to 
biotransformation. In vivo GLE and PIB weakly inhibit 
CYP3A4 and uridine 5′-diphospho-glucuronosyltransferase 
(UGT) 1A1 [6, 20].
3.5.4  Excretion
GLE is primarily hepatically excreted as 92.1% of a radio-
active dose was retrieved in feces. The t½ at steady state is 
6–9 h. PIB is also primarily excreted in feces (96.6%) and 
the t½ is 23–29 h [6, 20].
3.6  SOF/Velpatasvir (VEL)/Voxilaprevir (VOX)
3.6.1  Absorption
The pharmacokinetics of the combination tablet SOF/VEL/
VOX  (Vosesi®) is described in this section. VOX, VEL, and 
GS-331007 reach Cmax after approximately 4 h and SOF 
after 2 h. Compared with healthy individuals, SOF and 
GS-331007 pharmacokinetics were not altered in HCV-
infected patients. For VEL, the AUC and Cmax were 41% and 
39% decreased in patients, respectively. For VOX, the AUC 
and Cmax were both elevated by 260% when HCV-infected 
individuals and healthy volunteers were compared [8, 21].
When taken with food (type of meal not defined), the 
SOF AUC ∞ and Cmax increased from 64 to 114% and 9 to 
76%, respectively. For GS-331007, the Cmax was decreased, 
ranging from 19 to 35%. For VEL, the AUC ∞ and Cmax were 
increased, ranging from 40 to 166% and 37 to 187%, respec-
tively. The VOX AUC and Cmax increased, ranging from 
112 to 435% and 147 to 680%, respectively. Therefore, it is 
recommended that SOF/VEL/VOX is taken together with a 
meal [8, 21].
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3.6.2  Distribution
SOF, VEL, and VOX are highly bound to plasma proteins 
(61–65%, > 99%, and > 99%, respectively). For SOF and 
VEL this was concentration independent in the ranges of 
1–20 and 0.09–1.8 µg/mL, respectively. GS-331007 is not 
bound to plasma proteins. SOF is a substrate of P-gp and 
BCRP, VEL is a substrate of P-gp, OATP1B1/3, and BCRP, 
and VOX is a substrate of P-gp and BCRP [8, 21].
3.6.3  Metabolism
VOX is a CYP3A4 substrate; however, after a single radio-
active dose, approximately 91% of the circulating drug was 
the parent drug. VOX is an inhibitor of P-gp, BCRP, and 
OATP1B1/3 [8, 21].
See Sects. 3.1.3 and 3.4.3 for the metabolism of SOF and 
VEL, respectively.
3.6.4  Excretion
SOF is mainly renally excreted (80%) and the majority of 
the dose was GS-331007 (78%); only 3.5% was found as 
SOF. The t½ of SOF was 0.5 h and for GS-331007 this was 
29 h [8, 21].
As > 94% of VEL was retrieved in feces and 0.4% in 
urine, clearance of VEL is mainly hepatic. In feces, 77% 
of VEL was recovered as the parent drug. The t½ of VEL is 
around 17 h [7, 19].
The major route of excretion is biliary, as 94% of VOX 
was recovered in the feces. After a single dose, almost 40% 
was found as the parent drug and 22.1% as the metabolite 
des-[methylcyclopropylsulfonamide]-voxilaprevir and three 
other metabolites (< 10%) [8, 21].
4  Drug–Drug Interactions
As presented in Fig. 3, most DAAs are substrates and inhibi-
tors of drug transporters and CYP enzymes and, therefore, 
have the potential for DDIs. In this section the most impor-
tant classes of drugs with interactions with DAAs are briefly 
discussed. For more information, and for help in clinical 
decision-making, we recommend the HEP Drug Interactions 
website (www.hep-drugi ntera ction s.org) [22].
4.1  HIV Drugs
Antiretroviral drugs have a high potential for DDIs due to 
induction or inhibition of CYP3A and drug transporters. 
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
have inducing effects, predominantly on CYP3A4. For 
example, after coadministration with efavirenz, the EBR and 
GZR AUC decreased by 54% and 87% [17], respectively, 
and the VEL AUC by ~ 50% [7]. The preferred NNRTIs 
for coadministration with GLE/PIB, SOF/VEL, and SOF/
VEL/VOX are doravirine and rilpivirine [23, 24]. Concomi-
tant use of DCV with a CYP3A4 inducer, such as efavirenz, 
ertravirine, and nevirapine, requires an increase in dose from 
60 to 90 mg due to lower DCV exposure [25].
Boosted protease inhibitors (PIs) are inhibitors of 
CYP3A, OATP, and P-gp. Concomitant use of CYP3A4 
inhibitors, such as atazanavir/ritonavir and cobicistat-
boosted regimens, requires a decrease in DCV dose from 60 
to 30 mg because of decreased CYP3A4 metabolism result-
ing in elevated DCV plasma concentrations [26, 27]. Use 
of GLE/PIB with ritonavir-boosted atazanavir is, however, 
contraindicated due to extreme elevations in GLE and PIB 
plasma concentrations. The Cmin of GLE and PIB increased 
14.0-fold and ~ 1.3-fold, respectively [6]. As all boosted PIs 
are strong CYP3A4 inhibitors, they are not recommended 
with the GLE and PIB combination [17, 28].
SOF/VEL may be coadministered with any antiretroviral 
regimen including the boosted PIs atazanavir, darunavir, and 
lopinavir (boosted with ritonavir or cobicistat) without dose 
adjustment as no clinically relevant differences in pharma-
cokinetics of SOF/VEL were observed [29]. SOF/VEL/VOX 
with darunavir/ritonavir and atazanavir/ritonavir resulted in a 
2.4- and 4.3-fold increase in the VOX AUC, respectively, due 
to OATP1B, P-gp, and CYP3A inhibition and is therefore not 
recommended [8]. Pharmacokinetic data with other boosted 
PIs are lacking, but they are not recommended for use together 
with SOF/VEL/VOX either.
SOF/LDV increases tenofovir exposure due to inhibition 
of P-gp. This is particularly relevant when LDV is com-
bined with tenofovir disoproxil fumarate (TDF) because of 
the high tenofovir plasma concentrations [15, 30]. When 
combined with tenofovir alafenamide this drug interaction 
is not clinically relevant due to lower circulating tenofovir 
concentrations [31]. A comparable increase in the tenofovir 
plasma concentration is observed when TDF is combined 
with VEL [7, 8]. This increases the risk of tenofovir-related 
renal toxicity. Therefore, additional monitoring of renal 
function is advised.
The integrase inhibitors raltegravir, dolutegravir, and 
bictegravir have favorable interaction profiles and can be 
safely combined with DAAs [32]. The exception is cobi-
cistat-boosted [31] elvitegravir as this combination also 
strongly inhibits CYP3A4 and P-gp.
4.2  Immunosuppressive Drugs
Since HCV is a major cause of cirrhosis, which could result 
in liver transplantation, immunosuppressant agents are com-
monly used by HCV-infected patients. Therefore, potential 
DDIs should be considered when treating these patients with 
both DAAs and immunosuppressive agents.
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The immunosuppressive agent cyclosporine (ciclo-
sporin) is a perpetrator of DDIs as it is a strong inhibitor 
of OATP1B1. Coadministration with EBR/GZR resulted in 
a 15-fold increase of the GZR AUC. Higher GZR expo-
sure potentially leads to hepatotoxicity and coadministra-
tion is thus not recommended [17]. Similarly, combining 
cyclosporine 100 mg with GLE resulted in an increased 
AUC (37%) and the GLE AUC increased by 451% after a 
dose of 400 mg. Since cyclosporine seemingly has a dose-
dependent influence on OATP, a maximum of 100 mg/day is 
recommended [6]. For VOX, the AUC and Cmax increased by 
19- and 9.4-fold when combined with cyclosporine, respec-
tively. Therefore, SOF/VEL/VOX is not recommended in 
subjects using cyclosporine [8]. However, to overcome this 
drug interaction, therapeutic drug monitoring (TDM) of the 
DAA could be used when no other DAA treatment options 
are available.
Tacrolimus is a CYP3A4 substrate and its AUC increased 
by 43% and 1.45-fold after coadministration with EBR/GZR 
and GLE/PIB, respectively, due to CYP3A4 inhibition [6, 
17]. Additional monitoring or dose alterations may be nec-
essary as tacrolimus has a narrow therapeutic range. This 
DDI can be overcome by using frequent TDM when starting 
DAA therapy. We strongly recommend frequent monitoring 
of the tacrolimus plasma concentration when HCV-infected 
patients are treated, not only to overcome possible DDIs but 
also because in patients recovering from an HCV infection 
the tacrolimus plasma concentration can be altered due to 
altered CYP3A4 metabolism [33]. Significant pharmacoki-
netic DDIs are not expected with SOF/DCV, SOF/LDV, 
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SOF/VEL, and SOF/VEL/VOX as they do not influence 
CYP3A4 and tacrolimus.
4.3  Cardiovascular Drugs
DDIs with cardiovascular drugs have been previously dis-
cussed in a paper published in this journal [34]. In short, 
statins (HMG-CoA reductase inhibitors) are substrates for 
several drug transporters, such as P-gp, BCRP, OATP1B1, 
and CYP enzymes. Generally, coadministration of statins 
with DAAs results in an increase of the statin AUC, caus-
ing higher risk of toxicities such as myopathies. Therefore, 
caution is needed, and at least adjustment and close moni-
toring for statin adverse effects are needed. Given the short 
treatment duration of HCV therapy (only 8–12 weeks), tem-
porary discontinuation of the lipid-lowering drug may be 
considered as well.
The antiarrhythmic agent amiodarone causes clinically 
relevant DDIs with SOF-containing regimens: events of 
severe bradycardia occurred after concomitant use of ami-
odarone and SOF [35–37]. The mechanism behind it, how-
ever, remains uncertain [38], although it is thought to reflect 
a pharmacodynamic interaction enhancing the bradycardic 
effect of amiodarone. Because of the long and variable t½ 
(20–100 days) of amiodarone, the timing of starting or dis-
continuing amiodarone should be kept in mind as DDIs can 
have a prolonged effect.
Since all of the new oral anticoagulants (NOACs) are 
substrates for P-gp, and apixaban and rivaroxaban are 
also substrates for BCRP and CYP3A, there could be an 
increased risk of toxicity when these drugs are combined 
with DAAs. This possibly includes bleeding. For both GLE/
PIB and SOF/VEL/VOX, the dabigatran etexilate AUC 
and Cmax values were approximately 2- to 3-fold increased 
after concomitant use [6, 8]. Pharmacokinetic data after co-
administration of anticoagulants with other DAAs are not 
available, but similar results are expected. Therefore, these 
drugs should either not be used with DAAs or used with 
caution and careful monitoring when no other anticoagulant 
is possible [23].
4.4  Anticonvulsant Drugs
The first-generation anticonvulsant drugs (e.g., carbamaz-
epine, phenytoin, phenobarbital) are strong inducers of 
CYP3A4 and P-gp. These drugs decrease DAA exposure 
significantly after coadministration, which could result in 
decreased virological effectiveness. Accordingly, these 
drugs are either not recommended or contraindicated with 
all HCV regimens [23]. If no other antiepileptic treatment 
is possible, the most optimal anti-HCV therapy seems to be 
SOF with an increased dose of DCV [39].
4.5  Tuberculosis Drugs
In some parts of the world, for instance Eastern Europe, 
tuberculosis (TB) disease is a burden among HCV or HIV/
HCV co-infected patients. This is mainly caused by the fact 
that these diseases (including hepatitis B virus [HBV]) are 
prevalent in the same (vulnerable) groups, such as men 
who have sex with men, prisoners, people who inject 
drugs, and immigrants and refugees from high endemic 
countries [40].
TB disease can be treated with combination therapy, but 
compliance to therapy is very important due to resistance 
issues. The first-line drugs for the treatment of TB disease 
include isoniazid, rifampicin (rifampin), rifabutin, rifapen-
tine, ethambutol, and pyrazinamide [41, 42]. All current 
DAA regimens are contraindicated with rifampicin, rifabu-
tin, and rifapentine as all these drugs are strong inducers of 
CYP3A4. For example, the AUCs of both SOF and VEL 
were decreased with 72% and 82% and the Cmax by 77% and 
71% when combined with rifampicin 600 mg once daily. 
Comparable results are found with the other DAAs and it is 
expected that rifabutin and rifapentine also reduce plasma 
concentrations in the same manner as they are also strong 
CYP3A4 inducers. Thus, it is not recommended to treat 
patients with DAAs combined with rifampicin, rifabutin, 
or rifapentine (similar to anticonvulsant drugs, as noted in 
Sect. 3.7.4) [7, 19], making it almost impossible to treat 
a patient for HCV and TB disease at the same time as 
rifampicin is the cornerstone of current TB disease treat-
ment [41].
Isoniazid, ethambutol, and pyrazinamide are not expected 
to have any clinically relevant drug interactions with the 
DAA regimens as the metabolic pathways do not interfere 
with each other [22].
4.6  Acid‑Reducing Agents
Acid-reducing agents such as proton pump inhibitors (PPIs) 
and histamine  H2-receptor antagonists are drugs that influ-
ence gastric pH. Both LDV and VEL have pH-dependent 
absorption. VEL is a weak base which is insoluble in water 
(pH 7; 0.003  mg/mL) and solubility increases at pH 2 
(> 2 mg/mL) [43]. Clinically, this results in decreased expo-
sure of VEL when combined with PPIs such as omeprazole. 
When omeprazole (20 mg) was combined with SOF/VEL in 
fasted subjects, the AUC and Cmax of VEL decreased (36% 
and 37%). The VEL AUC and Cmax decreased even more 
when omeprazole 20 mg once daily (fasted) was taken 12 h 
before SOF/VEL intake (55% and 57%). The same dose of 
omeprazole administered 2 h before SOF/VEL, with food, 
also resulted in decreased AUC and Cmax values of 38% and 
48%. The most promising results were found when omepra-
zole 20 mg was taken 4 h after SOF/VEL was taken with 
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food; the AUC and Cmax only dropped 26% and 33% [7, 
19]. Our recommendation for VEL is not to combine it with 
acid-reducing agents except when it is really clinically nec-
essary and the PPI cannot be discontinued. Based on the 
results mentioned here, we advise use of omeprazole 20 mg 
once daily and administration of SOF/VEL with food 4 h 
before the PPI is used.  H2-receptor antagonists (famotidine 
40 mg twice daily or equivalent) should be taken together 
with SOF/VEL or separated by at least 12 h.
LDV solubility is also pH dependent as it is slightly solu-
ble at pH 2.3 but practically insoluble at pH 4–7.5 [44]. 
When SOF/LDV was coadministered with omeprazole 
20 mg once daily simultaneously, the AUC and Cmax were 
decreased by 4% and 11%. When the intake was separated 
by 2 h, the LDV AUC and Cmax were decreased by 42% and 
48% [15, 16]. As for VEL, we do not recommend SOF/LDV 
be combined with high-dose acid-reducing agents. However, 
if necessary it can be combined with omeprazole 20 mg once 
daily or famotidine 40 mg twice daily if taken at the same 
time as SOF/LDV. It is important to note that these recom-
mendations are based on pharmacokinetic changes of the 
DAAs and not on efficacy endpoints.
5  Efficacy and Toxicity
In this section the pharmacokinetic–pharmacodynamic (PK-
PD) relationship of the DAAs and the viral inhibition are 
described. Pharmacodynamics is defined as reduction of 
HCV-RNA virus when a patient is treated with the DAAs. 
To determine the optimal dose, there is a balance between 
the effect (HCV-RNA reduction) and toxicity (adverse 
effects, adverse events [AEs]).
ESM Table S2 provides an overview of the dose–response 
relationships of the DAAs. For most DAAs the approved 
dose is one of the highest dosages tested. This shows that all 
the DAAs were well-tolerated during the dose-finding and 
PK-PD studies. However, this also means that these dos-
ages are likely in the upper part of the s-curve (plateau) 
where the effect is maximal (Fig. 4). When these thoughts 
are translated to, for instance, drug interactions, this helps 
explain why the LDV + PPI drug interaction is marked from 
a pharmacokinetic perspective (absorption and exposure 
decreases) but may not be clinically relevant (since in most 
patients at least, you are still in the upper part of the PK-PD 
curve with no effect on SVR). It is also important when 
interpreting these PK-PD relationships to note that there is 
always variability between individual patients (inter-subject 
variation). This variation could have several causes such as 
physiology (age, sex), genetic factors influencing metabo-
lism (e.g., CYP polymorphisms) and drug transport (e.g., 
OCT or OATP polymorphisms), or environmental factors 
(smoking, nutrition, alcohol use).
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Fig. 4  Pharmacodynamic–pharmacokinetic relationship and factors influencing pharmacodynamics and pharmacokinetics. Every drug has a 
pharmacodynamic (= effect and toxicity) and pharmacokinetic (= exposure) relationship
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5.1  SOF/DCV
5.1.1  Efficacy
The combination of SOF/DCV is licensed to treat patients 
with all HCV genotypes; however, DCV is mostly used to 
treat HCV in patients infected with HCV genotypes 1, 2, 
3, and 4 [23]. In a dose-finding study, DCV was admin-
istered in doses of 1, 10, 30, 60, and 100 mg once daily. 
Geometric mean AUCs showed dose-proportional phar-
macokinetics. After 1 day of dosing, the HCV-RNA was 
decreased by ~ 3  log10 IU/mL for all study groups (except 
1 mg). The exposure–response analysis suggested a dose 
varying from 3 to 60 mg once daily [45].
Similarly, single and multiple doses of SOF 50, 100, 200, 
and 400 mg once daily were administered to HCV genotype 
1-infected patients for 3 days. The decline in HCV-RNA 
viral load was dose dependent and for 400 mg a HCV-RNA 
reduction of ~ 2 log10 IU/mL was seen (200 mg ~ 1 log10 IU/
mL) [46].
Due to good results in phase  II studies, SOF/DCV 
received early approval. These data are not described in this 
review as it mainly consists of data in combination with peg-
IFN and RBV. Later on, efficacy and safety were studied to 
a greater extent. The ANRS (France REcherche Nord&Sud 
Sida-hiv Hépatites) CO22 HEPATHER trial included DAA-
naïve HCV genotype 1-infected patients with and without 
cirrhosis. Overall, 92–99% of the patients achieved sus-
tained virological response (SVR) 12 weeks after treatment 
(SVR12). The SVR12 rates were 98% and 94% in those 
without and with cirrhosis, respectively [47]. In a real-world 
study in DAA-naïve HCV genotype 2-infected patients with 
and without cirrhosis, all 32 (100%) reached SVR12 [48]. 
In the ALLY-3 study (phase III), the overall SVR12 rate 
in HCV genotype 3-infected patients was 89%. Patients 
with and without cirrhosis yielded SVR12 rates of 63% and 
96%, respectively. So, SOF/DCV is not the ideal regimen 
for HCV genotype 3-infected patients with cirrhosis [49]. 
Another study showed that patients with advanced fibrosis 
or compensated cirrhosis obtained an overall SVR12 rate 
of 90%: 88% and 92% following 12 and 16 weeks of treat-
ment, respectively [50]. HCV genotype 4-infected patients 
yielded SVR12 rates of 92% in patients with cirrhosis or 
treatment-experienced patients without cirrhosis [51] (see 
ESM Table S3).
5.1.2  Toxicity
The most commonly reported adverse effects for the SOF/
DCV combination were fatigue, headache, and gastroin-
testinal complaints such as diarrhea and nausea. In sev-
eral studies, concomitant therapy with RBV resulted, as 
previously described [52], in anemia and leukopenia [47, 
51, 53–57]. Following an AE, ≤ 7% of the patients discon-
tinued treatment with SOF/DCV, with the exception of 
patients with a life expectancy of less than 12 months due 
to decompensated cirrhosis or recurrence of HCV follow-
ing a liver transplant, in whom 10% and 18%, respectively, 
discontinued therapy due to an AE [54].
5.2  SOF/LDV
5.2.1  Efficacy
A dose-ranging study using LDV 1, 3, 10, 30, and 90 mg 
for the duration of 3 days was performed in HCV-infected 
subjects. On day 3, the AUC during a dosing interval (AUC 
τ) varied from 34.0 to 3815.5 ng/mL for these dose ranges, 
showing dose-proportional pharmacokinetics. For all 
doses the median HCV-RNA reduction was > 3 log10 IU/
mL, showing comparable viral suppression over the dose 
range. In the same study the exposure–response relation-
ship of LDV was simulated. The AUC and maximal HCV-
RNA decline were used and for genotype 1a patients it was 
found that a dose of 30 mg would be optimal to have a > 95% 
antiviral response [58]. However, no formal dose/concentra-
tion–effect relationship has been established for the combi-
nation of SOF plus LDV.
SOF/LDV is an effective treatment in the dose of 
90 mg/400 mg once daily. The regimen can be used in 
patients infected with HCV genotypes 1a, 1b, 4, 5, and 6 
(12 weeks) in treatment-naïve patients with or without com-
pensated (Child–Pugh [CP] score A) cirrhosis. Addition-
ally, SOF/LDV (12 weeks) is also effective in treatment-
experienced HCV genotype 1b-infected patients [23]. In 
patients with an HCV-RNA viral load of < 6,000,000 IU/
mL, the SOF/LDV treatment duration can be decreased to 
8 weeks when patients are infected with genotype 1b [59, 
60]. Boerekamps et al. [61] even showed that 8 weeks of 
SOF/LDV can be used to treat both HCV and HIV/HCV 
co-infected patients with genotype 4-infected patients. The 
efficacy and safety of SOF/LDV were studied in the ION-1 
study, where treatment-naïve HCV genotype 1a-infected 
patients yielded SVR12 in 99% of individuals after 12 weeks 
of treatment without RBV. In patients with HCV genotype 1b 
infection, SVR12 rates of 100% were obtained after the same 
treatment regimen [62]. In the ION-2 study, 94% of treat-
ment-experienced HCV genotype 1-infected patients, includ-
ing those with cirrhosis, achieved SVR12 [63]. In a phase III 
study, treatment-naïve and treatment-experienced patients 
infected with HCV genotype 1 were treated for 12 weeks 
without RBV: 100% achieved SVR12, including those with 
compensated cirrhosis [64]. After 12 weeks of therapy 
with SOF/LDV, 95% of HCV genotype 4-infected patients 
achieved SVR12 in the SYNERGY trial [65]. Results were 
confirmed with SVR12 rates of 96% in treatment-naïve and 
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91% in treatment-experienced patients with HCV genotype 
4 [66]. HCV genotype 5-infected patients were treated in 
an open-label phase II study, in which 95% achieved SVR 
[67]. SVR rates of 64% and 96% were achieved in patients 
with HCV genotypes 3 and 6, respectively, in an open-label 
study [68]. In conclusion, the regimen containing LDV and 
SOF is effective in patients with genotypes 1, 4, 5, and 6 and 
has reduced efficacy to HCV genotype 3 (ESM Table S4).
5.2.2  Toxicity
The most frequently occurring AEs reported from studies 
with SOF/LDV were mild, being fatigue, headache, and 
nausea. In multiple studies no adverse effects at all were 
reported to occur in over 10% of the study population 
[69–71]. Less than 5% of the patients discontinued treat-
ment due to an AE in all studies.
5.3  EBR/GZR
5.3.1  Efficacy
EBR/GZR is an effective regimen when used for 12 weeks 
against HCV genotypes 1 and 4. It is approved for patients 
with renal insufficiency and compensated cirrhosis [23]. 
In a dose-finding study, patients with HCV genotype 1 or 
3 infection were treated with EBR (5–100 mg) for 5 days 
and GZR (10–800 mg) for 7 days (both monotherapy). For 
HCV genotype 1-infected patients treated with GZR with 
doses > 30  mg, the mean maximum HCV-RNA reduc-
tion was > 4.0  log10  IU/mL. For HCV genotype  3, this 
amount of HCV-RNA reduction was achieved follow-
ing doses > 400 mg. These data suggest that for GZR the 
dose–response plateau is reached at a dose of 50 mg once 
daily; however, this cannot be confirmed for HCV geno-
type 3-infected patients. For genotypes 1a and 1b the mean 
maximum HCV-RNA reduction was > 4.0 log10 IU/mL at a 
dose of EBR 50 mg. For genotype 3 the doses of EBR 50 
and 100 mg had a mean maximum HCV-RNA reduction 
of > 3.0 log10 IU/mL. These data suggest a dose of 50 mg of 
EBR is sufficient [72].
The combination of EBR/GZR is approved in the fixed-
dose combination of 50 mg/100 mg once daily for genotypes 
1 and 4. In the C-WORTHY trial, HCV genotype 1-infected 
patients were effectively treated (with or without cirrhosis, 
12–18 weeks) and SVR12 rates varied from 91 to 100% [73]. 
C-CORAL (treatment-naive ± cirrhosis) showed SVR12 of 
94% in patients with genotypes 1, 4, or 6 [74]. Jacobson 
et al. [75] performed an integrated analysis showing SVR 
rates varying from 89 to 100% when treating patients with 
CP-A (treatment-naive and treatment-experienced). In addi-
tion, genotype 1a patients with HCV-RNA > 800,000 IU/
mL had lower SVR rates than genotype 1a patients with 
HCV-RNA < 800,000  IU/mL (12  weeks: 91% vs. 98%; 
16 weeks + RBV: 94% vs. 100%). It was also shown that 
patients with non-structural protein (NS)5A baseline RASs 
had an SVR12 of 53% (16/30) after 12 weeks of treatment 
with EBR/GZR; this was increased to 100% (4/4) when 
treated for 16 weeks [75]. Therefore, in patients with a high 
viral load and patients with NS5A RASs, physicians should 
consider treating for 16 weeks with EBR/GZR.
The C-SALVAGE phase  II study was a hypothesis-
generating trial to study EBR/GZR + RBV for 12 weeks 
as a salvage therapy for genotype 1a/1b. Patients who did 
not respond to a licensed DAA-containing therapy were 
included, and overall an SVR of 96% was achieved [76].
Low SVR rates were found, varying from 45 to 57%, 
when treating genotype 3 patients for 12–18 weeks, respec-
tively (C-WORTHY), which fits the previous PK-PD results 
[77]. Therefore, SOF was added in the C-ISLE trial. This 
combination was highly effective as SVR12 rates over 94% 
were reported [78] (ESM Table S5).
5.3.2  Toxicity
Overall, EBR/GZR has a favorable safety profile with low 
discontinuation rates (≤ 5%). The exception was the ANRS 
HC34 REVENGE trial where patients with advanced fibro-
sis or compensated cirrhosis were treated for 24 weeks in 
combination with RBV, in which 15% (2/13) of the patients 
discontinued due to AEs [79]. The most frequently reported 
AEs were fatigue, headache, asthenia, nausea, rash, alanine 
aminotransferase (ALT)/aspartate aminotransferase (AST) 
increase, and alkaline phosphatase increase. These increased 
liver enzymes mostly recovered after treatment with EBR/
GZR and are related to the plasma concentration of GZR. 
The presence of cirrhosis is not a risk factor for this ALT/
AST increase [17].
5.4  SOF/VEL
5.4.1  Efficacy
The PK-PD relationship for VEL was established in a 
dose-ranging study with ascending doses of 5, 25, 50, 100, 
and 150 mg once daily given for 3 days to HCV genotype 
1a-infected patients. The reported AUC τ values after 3 days 
varied from 86.4 to 5003.0 ng∙h/mL for the doses of VEL 
5–50 mg, showing dose-proportional pharmacokinetics. 
For all dose ranges in HCV genotype 1a-infected patients, a 
maximal HCV-RNA decline of ≥ 3 log10 IU/mL was estab-
lished. For genotype 3, only the 150 mg dose had a maximal 
HCV-RNA decline > 3 log10 IU/mL [80].
Treatment with SOF/VEL for 12 weeks is highly effec-
tive in both treatment-experienced and treatment-naïve 
patients with all genotypes of HCV infection. The phase III 
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ASTRAL-1 trial in patients with HCV genotype 1a, 1b, 2, 4, 
5, and 6 infections yielded SVR12 rates varying from 97 to 
100% [81]. These results were confirmed by the ASTRAL-2 
trial (99% in genotype 2) [82] and multiple real-world stud-
ies in patients with all HCV genotypes [83, 84]. ASTRAL-3 
showed that patients with genotype 3 infection achieved 
SVR12 rates of 98% (treatment naïve without cirrhosis). 
Therefore, this regimen can be used for the treatment of 
HCV genotype 3-infected patients. However, lower rates 
were observed in patients with genotype 3 plus cirrhosis or 
treatment experience (91% and 90%, respectively). All these 
patients received 12 weeks of SOF/VEL without RBV [82]. 
Additionally, suboptimal results in HCV genotype 3 patients 
with compensated cirrhosis were reported (SVR12 78% and 
88%, respectively) [85, 86]. For patients with HCV genotype 
3 infection and cirrhosis, addition of a third drug to this regi-
men may be necessary, justifying the triple therapy of SOF/
VEL/VOX in this subpopulation (ESM Table S6).
5.4.2  Toxicity
The most frequently observed adverse effects from the 
phases II and III trials of SOF/VEL were headache, fatigue, 
nausea, and insomnia. As expected, combination therapy 
with RBV led to anemia in over 10% of the patients in two 
studies [87, 88]. Discontinuation rates due to an AE were 
low (≤ 5%) in all studies.
5.5  GLE/PIB
5.5.1  Efficacy
The dose–response relationship of GLE and PIB (both as 
monotherapy) was assessed in HCV genotype 1-infected 
patients for 3 days. The GLE dose ranged from 100 to 
700 mg and PIB from 15 to 400 mg. Both GLE and PIB 
have more than dose proportional pharmacokinetics. After 
a dose of GLE 1200 mg once daily, the AUC was 516-fold 
higher than with 200 mg once daily. In comparison, PIB 
120 mg once daily resulted in a 10-fold increased AUC 
compared with 30 mg once daily. Both increases are prob-
ably caused by saturation of efflux transporters. When PIB 
is combined with GLE (which is always the case), the expo-
sure is 3-fold higher than with PIB monotherapy [6, 20]. 
For GLE, the mean maximal decrease in HCV-RNA ranged 
from 4.1 to 4.3 log10 IU/mL. For PIB, HCV-RNA declines 
of > 3.4 log10 IU/mL were seen. The 15 mg dose of PIB 
resulted in a smaller decline in HCV-RNA than with the 
doses of 40, 120, and 400 mg [89].
This pan-genotypic regimen is highly effective when 
administered for 8 or 12 weeks in doses of 100 mg/40 mg 
once daily (treatment-naïve and treatment-experienced 
patients, with and without cirrhosis). Multiple phases II 
and III studies also yielded high rates of SVR12 in patients 
treated with GLE/PIB in the harder to treat HCV geno-
types 1b and 3. In the SURVEYOR phase II study, DAA-
naïve patients without cirrhosis received GLE/PIB for 8 or 
12 weeks and SVR12 rates varied from 97 to 100% [90]. The 
ENDURANCE studies reported SVR12 rates of 95% in non-
cirrhotic patients with HCV genotype 3. Shorter treatment 
is also possible, as SVR12 rates of 99% and 100% in HCV 
genotype 1-infected patients without cirrhosis after 8 and 
12 weeks of treatment, respectively, were reported [91]. The 
EXPEDITION-1 trial in HCV genotype 1–6 patients with 
compensated cirrhosis resulted in SVR12 rates of 99% [92]. 
In conclusion, GLE/PIB is a pan-genotypic regimen with 
high efficacy rates in all HCV genotypes, including treat-
ment-experienced patients and those with cirrhosis (ESM 
Table S7).
5.5.2  Toxicity
In general, GLE/PIB has a mild toxicity profile. The most 
commonly reported AEs were headache, fatigue, nasophar-
yngitis, and nausea. Some regimens comprising HCV PIs 
have been associated with hepatotoxicity (e.g., GZR) [93]. 
In contrast to these findings, clinically significant labora-
tory abnormalities for liver function were rare. Elevated 
ALT, AST, or alkaline phosphatase levels as common 
AEs were not reported in any of the studies. In addition, 
increased blood bilirubin and a total bilirubin of more than 
1.5–3.0 × the upper limit of normal were reported in only 
one study [94]. Low rates of discontinuation due to an AE 
(≤ 6%) were found with and without concomitant use of 
RBV in both cirrhotic and non-cirrhotic patients.
5.6  SOF/VEL/VOX
5.6.1  Efficacy
The PK-PD relationship of VOX was established in a study 
in HCV patients infected with all genotypes. Dependent on 
the genotype, doses of 50–300 mg were administered once 
daily for 3 days. The AUC τ values at day 3 of administration 
for all genotypes were 372.3, 1357.6, and 3926.9 ng∙h/mL 
for the doses of 50, 100, and 300 mg, respectively [95]. This 
means that VOX has more than dose-proportional pharma-
cokinetics [21]. For all genotypes, the doses ranging from 
100 to 300 mg once daily resulted in a mean maximal HCV-
RNA reduction of > 3 log10 IU/mL [95].
This pan-genotypic combination is highly effective and 
licensed to treat patients with and without compensated 
cirrhosis and patients that previously failed to respond on 
both peg-IFN/RBV and DAAs. Phase II studies showed 
high efficacy in treatment-naive patients with compensated 
cirrhosis and all genotypes (including genotype 3). SVR12 
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rates varied from 93 to 97% in patients with cirrhosis and 
rates of 88 to 100% without cirrhosis with varying treat-
ment durations of 6–12 weeks were achieved in patients with 
genotypes 2, 3, 4, or 6 [96]. Therefore, the phase III trials 
(POLARIS) continued with a treatment duration of 8 and 
12 weeks. The POLARIS 2/3 analysis showed an SVR12 
rate of 95% after treating a diverse group of 501 patients 
(treatment-naive, treatment-experienced, with and without 
compensated cirrhosis) [97].
In the POLARIS 1 trial where, among others, treat-
ment-experienced, HCV genotype 3-infected patients were 
treated for 12 weeks, an SVR12 rate of 100% was achieved. 
In the POLARIS 4 study an SVR of 99% was achieved in 
a comparable group of patients [98]. Taking these results 
into account, the current recommendation is to treat DAA 
treatment-experienced and/or compensated cirrhotic patients 
with this combination for 12 weeks and to treat treatment-
naïve patients for 8 weeks. However, in our opinion, this 
regimen should be used as salvage therapy due to the effi-
cacy of double medication regimens (ESM Table S8).
5.6.2  Toxicity
The toxicity profile of this combination regimen is mild. 
In the different trials the most frequently reported AEs 
were headache, diarrhea, fatigue, nausea, and constipation. 
In addition, the discontinuation rate due to AEs was low 
(≤ 3%) in all trials. As VOX is a PI, this combination should 
not be used in patients with CP-B/C cirrhosis as exposure 
increases, which could potentially cause safety issues (see 
Sect. 5.2).
6  Special Populations
The overall ranges of SVR12 for the combination treatment 
regimens in different study populations are presented in 
Table 3.
6.1  Hard to Cure Patients
In the era of DAA therapy, patients with genotype 3, cirrho-
sis, or who are treatment experienced were initially consid-
ered hard to cure (or hard to treat) as SVR rates were lower 
than with other patient populations. To increase the chance 
of achieving SVR, RBV was added to the first DAA regi-
mens or treatment durations were extended. In this section 
we discuss the current treatment options for those patients.
6.1.1  Genotype 3
Genotype 3 patients were easier to cure with peg-IFN/RBV 
than genotype 1 patients. Nevertheless, response rates were 
higher with the first approved DAA regimens; however, the 
SVR rates were lower than with genotype 1 or 4 patients. For 
example, a real-world study showed an SVR12 rate of 83% 
in genotype 3 patients with advanced fibrosis treated with 
SOF/DCV [99]. Additionally, 90% SVR12 was achieved in 
genotype 3 patients (with advanced fibrosis/compensated 
cirrhosis) treated with SOF/DCV/RBV for 12–16 weeks 
[50]. Due to good response rates, the preferred regimens, 
at this time, are SOF/VEL [82, 84–87, 100–104], GLE/PIB 
[90, 91, 105–107], or SOF/VEL/VOX [96–98, 108] for at 
least 12 weeks of treatment. With the currently available 
pan-genotypic treatment options, there no longer seems to 
be the need to approach HCV genotype 3-infected patients 
as hard to cure patients.
6.1.2  Treatment‑Experienced Patients
Treatment-experienced patients can be divided into two cat-
egories: patients who failed to respond to peg-IFN/RBV and 
those who failed to respond to DAA therapy. Both groups are 
considered hard to cure, but DAA-experienced patients are 
a higher risk due to the appearance of RASs. However, with 
the current treatment options, these treatment-experienced 
patients also obtain high SVR12 rates when DAA regimens 
are used that combine DAAs from the three currently avail-
able HCV drug classes.
Importantly, patients previously treated with peg-IFN/
RBV without cirrhosis can be treated as ‘normal’ patients. 
For all treatment regimens the SVR12 rates are up to 100%. 
The most successful results were achieved with treatment 
regimens consisting of SOF/DCV [47, 48, 53, 56, 109–114], 
GLE/PIB [94, 105, 106, 115–117], and SOF/VEL/VOX 
[96, 98, 108, 118]. Although efficacious, triple combination 
therapy is not indicated since double treatment regimens are 
also effective.
Limited data are available for the DAA-experienced 
patients. Excellent results were obtained in these patients 
with SOF/VEL/VOX [98] and GLE/PIB also showed good 
results for re-treatment of patients who previously failed to 
respond to NS5A inhibitors [116]. In patients with NS5A 
RASs, triple therapy with either SOF/VEL/VOX or the 
experimental combination SOF/GLE/PIB could be options 
[119].
With the DAA regimens currently available, peg-IFN/
RBV treatment-experienced patients have numerous options 
to attain successful virological eradication. The remaining 
hard to cure population is those patients who have previously 
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failed to respond to both PI and NS5A inhibitor-containing 
regimens, with the possibility of NS5A RASs.
6.1.3  Patients with Resistance‑Associated Substitutions
Resistance-associated substitutions (RASs) to DAAs, due to 
the error-prone nature of the HCV RNA polymerase, may 
be present at baseline and can significantly affect treatment 
outcomes and the achievement of SVR [120].
RASs in NS3 may affect virological results in patients 
treated with an NS3 inhibitor, such as GZR, GLE, and VOX. 
NS3 RASs at baseline were associated with lower rates of 
SVR12 after 12 weeks of treatment with EBR/GZR than in 
HCV-infected patients without this type of RAS [77, 78, 
121–123]. This pattern was also observed after treatment 
with GLE/PIB [91]. On the contrary, in a phase III trial 
12 weeks of treatment resulted in SVR12 rates of 100% (6/6) 
and 92% (34/37) in patients with and without baseline NS3 
RASs, respectively [107]. These findings may, however, be a 
result of small sample sizes. Similar patterns were observed 
for SOF/VEL/VOX, which implicates that NS3 RASs indeed 
are associated with lower virological efficacy rates [97, 98].
DCV, EBR, LDV, PBR, and VEL are NS5A inhibitors 
and are therefore expected to alter SVR rates in subjects with 
baseline NS5A RASs [55]. Similar results were achieved in 
studies with SOF/LDV [66, 70, 124–127], EBR/GZR [75, 
78, 121–123, 128–130], SOF/VEL [82–84, 86–88, 103], 
GLE/PIB [91, 107, 131], and SOF/VEL/VOX [97, 98].
Because of its interference with NS5B, a SOF-containing 
regimen could have decreased efficacy in patients with base-
line NS5B RASs. However, this does not seem to be such an 
issue as it is with the other RASs. Many patients are treated 
with SOF and only a few incidental reports of these kinds 
of NS5B RASs are presented. SVR12 rates in patients with 
NS5B RASs varied from 88 to 100% with all SOF-contain-
ing regimens [66, 70, 82, 84, 104, 126, 130, 132–138].
Although the SVR in patients with baseline RASs is 
somewhat lower than in those without RASs at baseline, 
overall rates for efficacy remain high even in this popula-
tion. Additionally, patients with baseline RASs for one pro-
tein have other treatment options in reserve that encounter 
another HCV protein.
6.2  Liver Cirrhosis
Chronic hepatitis may lead to progressive liver fibrosis and 
subsequently result in cirrhosis, which could alter the phar-
macokinetics and pharmacodynamics of a drug. We have 
previously described the possible issues with liver cirrhosis 
in more detail [139].
Total DCV Cmax and AUC values were lower in subjects 
with cirrhosis than in subjects with normal liver function 
after a single 30 mg dose of DCV. The DCV AUC was 43, DC
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38, and 36% lower in patients with mild (CP-A), moderate 
(CP-B), and severe (CP-C) hepatic impairment, respectively. 
For Cmax, the geometric mean is estimated to be at least 45% 
lower in patients with hepatic dysfunction. However, hepatic 
impairment has no clinically significant effect on unbound 
DCV concentrations and thus on exposure to the active frac-
tion [9, 140].
The steady-state AUC for SOF increased 126% and 143% 
in CP-B and CP-C patients, respectively, compared with 
controls after 7 days dosing of SOF 400 mg. The GS-331007 
AUC was increased by 18% and 9%, respectively [11]. After 
treatment with SOF/DCV combination therapy for 12 or 
24 weeks (according to disease severity), SVR12 rates of 
50–100% [47–50, 53–57, 112] were reached in CP-A/B/C 
patients. Lower rates of SVR12 (< 90%) were obtained in 
the studies with small sample sizes [54]. Accordingly, SOF/
DCV is a treatment option for CP-A/B/C patients without 
any dose adjustments needed (see Table 4).
Following a single dose of LDV 90 mg, HCV-uninfected 
patients with CP-C had no clinically relevant changes in 
LDV pharmacokinetics [141]. The effect of hepatic impair-
ment on the pharmacokinetics of a fixed-dose combination 
of SOF/LDV is expected to be similar to when SOF and 
LDV were administered separately. The safety and efficacy 
of 12 weeks of treatment with SOF/LDV with and without 
RBV was evaluated in HCV-infected patients with compen-
sated cirrhosis. Treatment resulted in high efficacy, irrespec-
tive of transplantation status [65, 67, 71, 126, 142–146]. In 
studies including CP-C decompensated cirrhotic patients, 
SVR12 rates were lower (40–92%), although retrieved from 
small sample sizes [144–147]. These patients seem to benefit 
from the addition of RBV.
Following administration of EBR 50  mg, the AUC 
decreased by 39, 28, and 12% and Cmax by 42, 31, and 42% 
in patients with CP-A, CP-B, and CP-C, respectively, com-
pared with healthy controls [148]. For GZR, however, the 
steady-state GZR exposure was 1.66-, 4.82-, and 11.67-
fold higher following varying doses of GZR (200, 100, 
and 50 mg, respectively) based on their hepatic function 
(CP-A, CP-B, and CP-C, respectively). Correspondingly, 
Cmax values increased, although AEs did not [148]. Based 
on these findings, GZR is contraindicated in patients with 
CP-B or CP-C hepatic impairment (see Table 4). EBR/GZR 
in patients with liver CP-A cirrhosis obtained high SVR12 
rates (90–100%) in all studies [73, 74, 78, 79, 122, 129]. 
Increased values of ALT, AST, and alkaline phosphatase 
were reported in some studies [73, 74, 78, 121, 129, 149, 
150]. The presence of cirrhosis was, however, not thought 
to be a risk factor for this elevation [17]. In summary, EBR/
GZR can be used in patients with CP-A with monitoring of 
liver function.
After a single dose of VEL 100 mg, the AUC was 17% 
lower and 14% higher in non-HCV patients with CP-B and 
CP-C cirrhosis, respectively [151]. Additionally, subjects 
with compensated cirrhosis (CP-B) received either SOF/
VEL for 12 weeks with or without RBV or SOF/VEL for 
24 weeks. The VEL AUC τ was similar and SOF exposure 
was higher (~ 100%) [152]. Efficacy of SOF/VEL in CP-A 
patients was high, with SVR12 rates up to 100% after treat-
ment for 12 or 24 weeks [81–83, 86, 101–103]. In CP-B 
patients, SVR rates increased with use of RBV: from 83 to 
94% [87]. Efficacy seems to decrease with increasing liver 
impairment based on lower SVR rates in CP-C patients 
[88]. Therefore, SOF/VEL is not the therapy of choice in 
CP-C and CP-B patients and therefore RBV should be added 
(12 weeks of treatment).
A single dose of PIB 120 mg resulted in an AUC increase 
of 51%, 31%, and 5.2-fold in patients with CP-A, CP-B, 
and CP-C, respectively. For the fixed-dose combination of 
GLE/PIB, the GLE AUC increased by 33%, 2.0-fold, and 
11-fold in patients with CP-A, CP-B, and CP-C, respec-
tively, compared with normal subjects. GLE is therefore 
contraindicated in CP-C patients. The PIB AUC differed by 
26% or less for patients with CP-A or CP-B cirrhosis, and 
increased to 2.1-fold for those with CP-C [153]. The results 
for efficacy of GLE/PIB in patients with CP-A cirrhosis are 
Table 4  Dose adjustments in patients with cirrhosis
qd once daily
a Clinical and hepatic laboratory monitoring is indicated with decompensated patients
b Not recommended as safety and efficacy not studied in patients with Child–Pugh score B
Drug Normal dose Child–Pugh score A Child–Pugh score B Child–Pugh score C References
Daclatasvir 60 mg qd 60 mg qd 60 mg qd 60 mg qd [9, 10]
Sofosbuvir/ledipasvir 400 mg/90 mg qd 400 mg/90 mg qd 400 mg/90 mg qd 400 mg/90 mg qd [15, 16]
Elbasvir/grazoprevir 50 mg/100 mg qd 50 mg/100 mg qd Contraindicate Contraindicated [17, 18]
Sofosbuvir/velpatasvir 400 mg/100 mg qd 400 mg/100 mg qd 400 mg/100 mga 400 mg/100 mga [7, 19]
Glecaprevir/pibrentasvir 100 mg/40 mg qd 100 mg/40 mg qd Not  recommendedb Contraindicated [6, 20]
Sofosbuvir/velpatasvir/vox-
ilaprevir
400 mg/100 mg/100 mg qd 400 mg/100 mg/100 mg qd Not recommended Not recommended [8, 21]
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promising. Overall, 96–100% of patients achieve SVR12 fol-
lowing 12 weeks of treatment without [92, 105, 107, 154] or 
with RBV [105]. GLE/PIB is not recommended in patients 
with decompensated cirrhosis, but may be effective in treat-
ing CP-A patients.
No pharmacokinetic studies of the triple combination 
therapy SOF/VEL/VOX for HCV-infected patients with 
cirrhosis were performed. Since VOX is a PI, it is expected 
that it will increase hepatotoxicity and should therefore 
not be used in patients with decompensated cirrhosis (see 
Table 4). The treatment regimen was found to be highly 
effective in patients with CP-A cirrhosis, with SVR12 rates 
of 80–100% [96, 97, 108, 118, 155]. However, none of 
these studies included patients with decompensated cirrho-
sis, which makes implementation to all types of cirrhotic 
patients difficult.
6.3  Transplant Patients
HCV infection has a negative impact on both patient and 
graft survival in kidney transplant recipients compared to 
those without HCV infection [156]. Additionally, DDIs 
with immunosuppressants also make this population prone 
to negative treatment outcomes (see Sect. 4.2).
Efficacy and safety have not been studied thoroughly 
in transplant patients, but, to date, results seem promising 
that DAA treatment is safe and effective. For kidney trans-
plant recipients, SOF/LDV therapy resulted in an SVR12 
of 100% following treatment for 12 or 24 weeks without 
RBV. No significant changes in estimated glomerular filtra-
tion rate (eGFR) were observed during and after treatment 
[157]. These successful virological results were confirmed 
in several clinical trials and real-world studies [158–161]. 
High efficacy rates with favorable safety profiles in kidney 
transplant recipients were also retrieved with SOF/DCV 
[159–161] and GLE/PIB [131]. DAA therapy was well-tol-
erated in all studies, with mild AEs and laboratory abnor-
malities being infrequent.
Liver transplant recipients with HCV recurrence obtained 
an SVR rate of 94% following SOF/DCV/RBV for 12 weeks. 
Similar results were achieved in other studies with liver 
transplant patients [54, 110, 162]. Efficacy rates for SOF/
LDV varying from 50 to 100% were seen in HCV recurrent 
liver transplant recipients following the fixed-dose combina-
tion of SOF/LDV [69, 124, 146]. SVR12 rates lower than 
85% were only achieved in studies with low numbers of 
included patients (n < 10) [124]. Comparably, 12 weeks of 
treatment with SOF/VEL and GLE/PIB resulted in SVR12 
rates of 96% and 89%, respectively, in liver transplant recipi-
ents [104, 131]. Therapies were generally well-tolerated with 
no serious adverse effects, laboratory abnormalities, or graft 
transplant rejection in relation to the treatment.
In conclusion, DAA therapy seems to be effective and 
safe in transplant patients with no therapy alterations being 
necessary.
6.4  Renal Impairment
Two SOF-free regimens are available: EBR/GZR and GLE/
PIB. EBR and GZR are both minimally (< 1%) renally 
excreted; it is therefore not expected that overall clearance 
of either drug will be affected. After normal doses, EBR/
GZR exposure is increased by 50–86% in both advanced 
chronic kidney disease (CKD) patients with and without 
HCV infection compared with healthy controls. For patients 
with end-stage renal disease (ESRD), EBR and GZR expo-
sure was not significantly affected. Also, the steady-state 
pharmacokinetics of EBR and GZR were not influenced by 
dialysis [17, 18]. The efficacy and safety of EBR/GZR in 
patients with renal impairment were studied in multiple tri-
als and SVR12 varied from 94 to 100% in various popula-
tions [149, 163–165]. Therefore, this regimen is safe and 
effective for patients with renal impairment, requiring no 
dose adjustment (see Table 5).
Renal excretion of both GLE and PIB are minimal (< 4%). 
For both drugs, the AUC was increased up to 13, 30, 45, 
and 56% in subjects with mild, moderate, and severe renal 
impairment or ESRD, respectively, compared with normal 
subjects [166]. The efficacy and safety of GLE/PIB were 
studied in patients with severe renal impairment (CKD stage 
4 or 5): the SVR12 rate was 98% after treatment with the 
fixed-dose combination of GLE/PIB for 12 weeks [105]. 
These results were confirmed with an SVR12 rate of 100% 
in patients with severe renal dysfunction and prior DAA 
treatment [106]. This treatment, therefore, is considered to 
be effective and safe in patients with severe renal insuffi-
ciency and no dose adjustments are required (see Table 5).
SOF is mainly renally excreted and reduced clearance 
can be expected in patients with renal dysfunction [11]. 
Concerns have risen due to substantially higher concen-
trations of the primary metabolite of SOF, GS-331007, 
in these patients (see Fig. 2). Patients with mild, moder-
ate, and severe renal insufficiency obtained increased SOF 
AUC values of 61, 107, and 171%, respectively, compared 
with controls. GS-331007 AUC values were elevated by 55, 
88, and 451%, respectively, so accumulation could occur 
[167]. Therefore, SOF-free regimens are generally preferred 
in patients with severe renal impairment (eGFR < 30 mL/
min/1.73 m2). In all other patients, restrictions regarding 
SOF are unnecessary [23].
However, increased exposure of GS-331007 is not associ-
ated with increased toxicity [12]. Due to the metabolism of 
SOF, it makes pharmacological sense to give a full dose of 
400 mg to patients with impaired renal function. The rea-
son for this is that we need to achieve high enough active 
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metabolite (GS-461203) concentrations in the liver for the 
antiviral action of SOF. Lower doses possibly result in lower 
active metabolite concentrations and response rates (see 
Sect. 4). It has been shown that SOF in standard doses is 
well-tolerated in patients with renal impairment [160, 168, 
169] and that alternate dosing of LDV/SOF in hemodialy-
sis patients yielded SVR12 rates of 91% [170]. In patients 
undergoing dialysis, a 95% SVR12 rate was achieved after 
SOF/VEL use for 12 weeks. The safety of this combination 
regimen was consistent with advanced renal disease and was 
well-tolerated [171]. In case no safer DAA options are avail-
able, e.g., in patients with other co-morbidities, treatment 
with SOF may therefore be acceptable.
6.5  Hepatitis C Virus (HCV)/HIV Co‑Infection 
and Hepatitis B Virus/HCV Co‑Infection
Historically, HCV/HIV co-infected patients were harder to 
treat patients, as SVR rates were lower in the peg-IFN/RBV 
era than in HCV mono-infected patients. However, SVR12 
rates after treatment with DAA regimens in HCV/HIV co-
infected patients are comparable with HCV mono-infected 
patients and this is extensively shown in the literature [52, 
56, 111, 114, 123, 125, 128, 137, 172–174].
HBV co-infected patients have a potential risk of HBV 
reactivation during or after HCV clearance, although this 
remains unpredictable [175]. The efficacy of HCV therapy 
in HBV/HCV co-infected patients was high (SVR12 100%) 
with SOF/LDV therapy for 12 weeks. Approximately two-
thirds of the patients had an increased HBV DNA level dur-
ing treatment, although this was not associated with any 
signs or symptoms. Only 2 of the 111 included patients 
required HBV therapy during SOF/LDV treatment. No 
(serious) AEs were reported and no patients discontin-
ued treatment [70]. Based on this study, there seems to be 
no reason to treat HBV co-infected patients differently to 
mono-infected patients. Therefore, HBV/HCV co-infected 
patients should be treated with the same anti-HCV treatment 
regimens as HCV mono-infected patients, keeping the HBV 
reactivation in mind—meaning that HBV DNA and ALT 
flares should be monitored at least every 4–8 weeks and 
3 months post treatment according to American Association 
for the Study of Liver Diseases (AALSD) guidance [176]. 
Patients that are hepatitis B surface antigen (HBsAg)-nega-
tive, antibody to hepatitis B core antigen (anti-HBc)-positive 
have a low reactivation risk and ALT should only be moni-
tored at baseline, end of treatment, and during follow-up 
[176].
6.6  Bleeding Disorders
Since treatment with interferon and RBV are associated 
with anemia, anti-HCV therapy has often been withheld in 
patients with bleeding disorders. Several phases II and III 
studies have examined the safety and efficacy of DAA treat-
ment regimens in this special population. Results in patients 
Table 5  Dose adjustments in patients with renal impairment
eGFR estimated glomerular filtration rate, qd once daily
a Not recommended as safety and efficacy has not been studied in patients with eGFR < 30 mL/min
Drug Normal dose eGFR Removed by 
hemodialysis
References
30–50 mL/min 10–30 mL/min < 10 mL/min
Daclatasvir 60 mg qd 60 mg qd 60 mg qd 60 mg qd Unlikely, high 
protein binding
[9, 10]
Sofosbuvir/ledi-
pasvir
400 mg/90 mg qd 400 mg/90 mg qd Not 
 recommendeda
Not 
 recommendeda
Ledipasvir: 
unlikely
GS-331007: yes, 
53%
[7, 19]
Elbasvir/grazo-
previr
50 mg/100 mg qd 50 mg/100 mg qd 50 mg/100 mg qd 50 mg/100 mg qd No [15, 16]
Sofosbuvir/vel-
patasvir
400 mg/100 mg qd 400 mg/100 mg qd Not 
 recommendeda
Not 
 recommendeda
Velpatasvir: 
unlikely
GS-331007: yes, 
53%
[6, 20]
Glecaprevir/
pibrentasvir
100 mg/40 mg qd 100 mg/40 mg qd 100 mg/40 mg qd 100 mg/40 mg qd No [17, 18]
Sofosbuvir/vel-
patasvir/voxil-
aprevir
400 mg/100 mg/100 mg 
qd
400 mg/100 mg/100 mg 
qd
Not recom-
mended
Not recom-
mended
Velpatasvir and 
voxilaprevir: 
unlikely
GS-331007: yes, 
53%
[8, 21]
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with bleeding disorders do not seem to differ from those 
in patients without these conditions [122, 135, 177–181]. 
Recommendations for HCV treatment in this special popula-
tion are therefore equal to those without a bleeding disorder. 
However, as several RBV-free regimens are available, the 
preferred option is to treat these patients with the RBV-free 
regimens of SOF/VEL or GLE/PIB.
6.7  Children and Adolescents
Mother-to-child transmission of HCV is the most common 
source of HCV infection in children; however, treatment 
of HCV-infected newborns is not yet possible [182, 183]. 
Therefore, children can be treated (see below) or HCV treat-
ment during pregnancy is an option, not only to cure mater-
nal HCV but also to reduce the incidence of pediatric HCV 
cases. With the introduction of RBV-free DAA treatment 
combinations, which are highly effective and show a favora-
ble safety profile in preclinical animal studies, treatment dur-
ing pregnancy seems realistic in the nearby future [184].
Children and adolescents may require treatment altera-
tions compared with adults due to differences in pharma-
cokinetics that potentially lead to efficacy and/or safety 
issues in this population. Administration of half of the 
adult fixed-dose of SOF/LDV in children (6 to < 12 years) 
resulted in comparable exposure to that in adults exposed 
to the fixed-dose combination: the AUC was 13% lower, 
16% higher, and 34% lower for LDV, SOF, and GS-331007, 
respectively. The Cmax was 16, 39, and 6% higher for these 
three compounds. An SVR of 99% was achieved in these 
DAA-naïve children with genotypes 1, 3, or 4 HCV infec-
tion [134].
Exposure in adolescents (12 to < 18 years) was com-
parable with that in adults following the adult fixed-dose 
combination of SOF/LDV: SOF, GS-331007, and LDV 
AUC τ increased by 60, 5, and 27%, respectively, and Cmax 
was 56, 39, and 62% higher, respectively [132]. Efficacy 
was also comparable with that in adults, as all 40 adoles-
cents (treatment-naïve, treatment-experienced, genotype 
4) achieved SVR when treated with LDV/SOF [185]. The 
SVR12 rate was 98% in HCV genotype 1-infected adoles-
cents (12–17 years) with and without compensated cirrhosis 
[132]. No serious AEs were reported in any of the studies.
Weight-based (≥ 45  kg: 400  mg/60  mg; 17–45  kg: 
200 mg/30 mg) SOF/DCV resulted in SVR12 rates of 97% in 
HCV genotype 4-infected adolescents (12–17 years) [186]. 
In a study with patients aged 8–18 years, SVR12 was 98% 
after SOF/DCV 400 mg/60 mg per 1.7 m2 [187].
At present, DAA therapy seems to be effective and safe 
(probably after dose adjustments based on bodyweight) in 
children and adolescents; however, additional studies may 
be necessary to confirm these statements.
7  Conclusion
In this descriptive review, we have provided an overview of 
the clinical pharmacokinetics and pharmacodynamics, in 
terms of efficacy and toxicity, of the DAA combination regi-
mens for the treatment of chronic HCV. Although we have 
listed all available treatment DAA regimens and options, no 
differences have been discussed in pricing and/or availability 
of the regimens. One should consider that in some counties 
only the pan-genotypic regimens SOF/VEL and GLE/PIB are 
available as first-line agents. In our opinion, SOF/VEL/VOX 
should be preserved as the salvage regimen for DAA failures.
We have also discussed the relationship between the phar-
macokinetics of the DAAs and efficacy or toxicity in patients 
with liver cirrhosis, liver transplantation, renal impairment, 
HBV or HIV co-infection, and bleeding disorders, and in 
children and adolescents.
As the development of treatments for HCV therapy is 
thought to have come to an end, this review gives a complete 
overview of all possible treatment options for chronic hepa-
titis C in well-resourced countries. This aids in ensuring that 
making informed decisions in clinical practice is feasible 
and physicians, pharmacists, and nurse practitioners are edu-
cated to effectively and safely treat HCV-infected patients.
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